lesinurad
Sign in to saveAlso known as RDEA 594, Zurampic®, RDEA-594, RDEA594
Lesinurad (brand name Zurampic) is a urate transporter inhibitor for treating high blood uric acid levels associated with gout. It is recommended only as an adjuvant with either allopurinol or febuxostat when these medications are not sufficient.
Research
183 papers- Lesinurad.2012
- Lesinurad Therapy and CYP2C9 Genotype.2012
- Lesinurad: First Global Approval.Drugs · 2016
- Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout.Drugs in context · 2019
- Lesinurad: A Review in Hyperuricaemia of Gout.Drugs & aging · 2017
via PubMed
Wikidata facts
- Subclass of
- carboxylic acid
- Mass
- 402.99901
- Has use
- medication
Show 5 more facts
- World Health Organisation international non-proprietary name
- lesinurad
- chemical formula
- C₁₇H₁₄BrN₃O₂S
- canonical SMILES
- C1CC1C2=CC=C(C3=CC=CC=C23)N4C(=NN=C4Br)SCC(=O)O
- Commons category
- Lesinurad
- physically interacts with
- Solute carrier family 22 member 12
via Wikidata · CC0
~5 min read
Encyclopedic overview
13 sectionsContents
- Medical uses
- Contraindications
- Adverse drug reactions
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Pharmacogenomics
- Chemistry
- See also
- References
- Further reading
- External links
{{Infobox drug | drug_name = | type = | IUPAC_name = 2-{[5-Bromo-4-(4-cyclopropyl-1-naphthyl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid | image = Lesinurad.svg | image_class = skin-invert-image | width = 180 | image2 = Lesinurad ball-and-stick model.png | image_class2 = bg-transparent
| pronounce = | tradename = Zurampic | Drugs.com = | MedlinePlus = a616015 | DailyMedID = Lesinurad | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_US = | pregnancy_category = | licence_EU = yes | legal_AU = S4 | legal_AU_comment = | legal_CA = | legal_DE = | legal_NZ = | legal_UK = | legal_US = Rx-only | legal_UN = | legal_status = | routes_of_administration = Oral (tablets)
Excerpted from Wikipedia’s “lesinurad” article, available under the CC BY-SA 4.0 licence.